Tag: BioPharmX

September 9, 2019 Off

BioPharmX posts $2.6 net loss in second quarter, seeks for strategic partnership transaction

BioPharmX posted net loss for the second quarter ended July 31, 2019 was $2.6 million, or $0.22 per share, compared with a net loss of $4.4 million, or $0.58 per share, during the prior fiscal year’s second quarter.

March 4, 2019 Off

BioPharmX enrolls patients to test new drug for skin condition rosacea

By Dino Mustafić

BioPharmX Corporation has enrolled patients for its Phase 2b testing BPX-04, a new drug limited by U.S. law to investigational use, topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea.